Protecting transplanted lungs

Primary graft dysfunction (PGD)—acute lung injury that develops within 72 hours of lung transplantation—is a major cause of illness and death after transplant. The mechanisms leading to PGD are not well understood, and there are no specific therapeutic interventions.

Ciara Shaver, MD, Ph.D., Lorraine Ware, MD, and colleagues, explored the role of cell-free hemoglobin (normally located inside ) in PGD.

The investigators found that elevated preoperative cell-free hemoglobin was associated with increased risk of PGD in lung transplant patients. In isolated human lungs and cultures of pulmonary endothelial cells (the cells that line blood vessels), they showed that cell-free hemoglobin increased , or "leakiness."

Treatment with acetaminophen, a drug that counters the oxidizing action of hemoglobin, prevented the increased permeability in isolated lungs and .

The findings, reported in JCI Insight, suggest that cell-free hemoglobin contributes to PGD by increasing vascular permeability and that acetaminophen may be a novel treatment to prevent PGD.


Explore further

Genotype may identify complication likelihood in sickle cell patients

More information: Ciara M. Shaver et al. Cell-free hemoglobin promotes primary graft dysfunction through oxidative lung endothelial injury, JCI Insight (2018). DOI: 10.1172/jci.insight.98546
Citation: Protecting transplanted lungs (2018, February 13) retrieved 21 August 2019 from https://medicalxpress.com/news/2018-02-transplanted-lungs.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
1 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more